The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Viral Vaccine Cell Culture Media Market Distribution by Type of Cell Culture (Adherent and Suspension), Type of Media (Animal Component Free, Protein Free and Serum Free), Scale of Operation (Clinical Operations and Commercial Operations), Type of End-User (Industry Players and Non-Industry Players), and Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    March 2022

  • Pages
    180

  • View Count
    885

Example Insights

Viral-Vaccine-Cell-Culture-Media-Market-Context Viral-Vaccine-Cell-Culture-Media-Market-List-of-viral-vaccine Viral-Vaccine-Cell-Culture-Media-Market-Distribution-by-Type-of-CC-Media Viral-Vaccine-Cell-Culture-Media-Market-Competitiveness-Analysis
Viral-Vaccine-Cell-Culture-Media-Market-Patent-Analysis Viral-Vaccine-Cell-Culture-Media-Market-Partnerships-and-Collaborations Viral-Vaccine-Cell-Culture-Media-Market-Vaccine-Developers Viral-Vaccine-Cell-Culture-Media-Market-Brand-Positioning-Analysis
Viral-Vaccine-Cell-Culture-Media-Market-Demand-Analysis Viral-Vaccine-Cell-Culture-Media-Market-Optimistic-Scenarios Viral-Vaccine-Cell-Culture-Media-Market-Distribution-by-Scale-of-Operation  

Overview

Over the past few years, a number of advanced vaccines targeting a myriad of disease indications have received approval from various regulatory authorities. Post the onset of COVID-19, there has been a surge in the demand for viral vaccines. In fact, it is estimated that more than 4.5 billion people, across the globe, have received at least a single dose of COVID-19 vaccine. In other words, around 60% of the global population has been vaccinated against COVID-19. However, as the global population continues to rise, the demand for such vaccines is likely to be there in the foreseen future as well. Taking into consideration the prevalent trends, the global vaccines market is anticipated to be worth around USD 100 billion in 2025. Amidst the recent initiatives in this context, several viral vaccine media developers have established various partnerships for the clinical and commercial manufacturing of viral vaccines.

Vaccine manufacturing is a highly regulated and challenging process; specifically, the production of viral components or whole viruses further adds to the complexity. Additionally, it is paramount for vaccine cultures to be devoid of any contamination and be highly effective. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for vaccines manufacturing. As a matter of fact, the recent surge in vaccine demand amidst the COVID-19 pandemic has served to facilitate a strong case for organizations to opt such media for the development and manufacturing of large quantities of vaccines. In fact, players engaged in this domain have shifted their focus towards serum free and animal component free media to carry out vaccine manufacturing owing to the various benefits offered by these media formulations, including low contamination rate. Given that the demand for viral vaccine is indubitably rising, the corresponding opportunity for viral vaccine cell culture media is expected to witness steady growth, over the next decade.

Scope of the Report

The “Viral Vaccine Cell Culture Media Market Distribution by Type of Cell Culture (Adherent and Suspension), Type of Media (Animal Component Free, Protein Free and Serum Free), Scale of Operation (Clinical Operations and Commercial Operations), Type of End-User (Industry Players and Non-Industry Players), and Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and the likely future potential of the viral vaccine cell culture market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:

  • A detailed overview of the overall market landscape of players engaged in the development of viral vaccine cell culture media, along with the information on their year of establishment, company size, location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 80 viral vaccine cell culture media, based on several relevant parameters, such as type of vaccine (protein subunit, viral vector, whole virus), type of cell culture (adherent and suspension), type of cell culture media (serum free, animal component free, protein free), purpose of media (Vero cell lines, human embryonic kidney (HEK) cell lines, Madin-Darby canine kidney (MDCK) cell lines, baby hamster kidney (BHK) cell lines, Madin-Darby bovine kidney  (MDBK) cell lines, other cell lines), media formulation (liquid and powder), and application area (research use and manufacturing). 
  • Elaborate profiles of prominent players (shortlisted based on number of products being offered) engaged in the development of viral vaccine cell culture media. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), product portfolio, recent developments and an informed future outlook.
  • An analysis of the recent developments and initiatives within the viral vaccine cell culture media industry, highlighting information on several partnerships and collaborations and expansion initiatives that have taken place in this domain, during the period 2015-2021.
  • An in-depth analysis of more than 130 vaccine developers and 50 vaccine contract manufacturers that are likely to partner with viral vaccine cell culture media providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other vaccine development and manufacturing related capabilities.
  • An in-depth product competitiveness analysis of viral vaccine cell culture media based on supplier power (in terms of expertise of the developer) and key product-related specifications (such as type of media, purpose of media, application area, type of vaccine, media formulation).
  • An elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment and company size), highlighting the current perceptions regarding their proprietary brands across viral vaccine cell culture media.
  • Insightful patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 3400 patents that have been filed / granted for viral vaccine cell culture media, between 2015 and 2021 (till November), highlighting key trends associated with these patents, across type of patents, publication year, issuing authorities involved, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis. 
  • An informed estimate of the annual demand for viral vaccine cell culture media (in terms of volume of media required for total number of cells), based on key geographical regions.

One of the key objectives of this report was to evaluate the current opportunity and the future potential associated with the viral vaccine cell culture media market, over the coming decade. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of cell culture (adherent and suspension) [B] type of cell culture media (animal component free, protein free and serum free), [C] scale of operation (clinical operations and commercial operations), [D] type of end-user (industry players and non-industry players), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players engaged in the development of viral vaccine cell culture media?
  • Which type of cell culture is most commonly offered by viral vaccine cell culture media developers?
  • What type of partnership models are commonly adopted by stakeholders engaged in this industry?
  • What is the relative competitiveness of different viral vaccine cell culture media?
  • Who are the most likely partners for vaccine cell culture media developers?
  • What are the key challenges currently faced by stakeholders in this industry?
  • What are the anticipated future trends related to viral vaccine cell culture media developers?
  • How is the current and future market opportunity likely to be distributed across key market segments? 

Contents

Chapter Outlines

Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of viral vaccine cell culture media market and its likely evolution in the mid to long term. 
 
Chapter 3 provides a general introduction to vaccine cell culture media. It further includes a detailed discussion on the vaccine components, historical evolution and development of viral vaccines, along with information on the types of viral vaccine, cell culture and cell culture media. Furthermore, it provides a brief overview of the advantages offered by cell culture media and their key limitations.
 
Chapter 4 provides a detailed overview of the overall market landscape of players engaged in the development of viral vaccine cell culture media, along with the information on their year of establishment, company size, location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 80 viral vaccine cell culture media, based on several relevant parameters, such as type of vaccine (protein subunit, viral vector, whole virus), type of cell culture (adherent and suspension), type of cell culture media (serum free, animal component free, protein free), purpose of media (Vero cell lines, HEK cell lines, Madin-Darby canine kidney (MDCK) cell lines, baby hamster kidney (BHK) cell lines, Madin-Darby bovine kidney  (MDBK) cell lines, other cell lines), media formulation (liquid and powder), and application area (research use and manufacturing).

Chapter 5 features elaborate profiles of prominent players (shortlisted based on number of products being offered) engaged in the development of viral vaccine cell culture media. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), product portfolio, recent developments and an informed future outlook.

Chapter 6 provides detailed analysis of the recent developments and initiatives within the viral vaccine cell culture media industry, highlighting information on several partnerships and collaborations and expansion initiatives that have taken place in this domain, during the period 2015-2021.

Chapter 7 features an in-depth analysis of more than 130 vaccine developers and 50 vaccine contract manufacturers that are likely to partner with viral vaccine cell culture media providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other vaccine development and manufacturing related capabilities.

Chapter 8 features an in-depth product competitiveness analysis of viral vaccine cell culture media based on supplier power (in terms of expertise of the developer) and key product-related specifications (such as type of media, purpose of media, application area, type of vaccine, media formulation).

Chapter 9 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of year of establishment and company size), highlighting the current perceptions regarding their proprietary brands across viral vaccine cell culture media.

Chapter 10 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 2800 patents that have been filed / granted for viral vaccine cell culture media, between 2015 and 2021 (till November), highlighting key trends associated with these patents, across type of patents, publication year, issuing authorities involved, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis. 

Chapter 11 provides an informed estimate of the annual demand for viral vaccine cell culture media (in terms of volume of media required for total number of cells), based on key geographical regions.

Chapter 12 features a detailed market forecast analysis, highlighting the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of cell culture (adherent and suspension) [B] type of cell culture media (animal component free, protein free and serum free), [C] scale of operation (clinical operations and commercial operations), [D] type of end-user (industry players and non-industry players), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 13 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of the discussion(s) that were held key stakeholders in the industry. 

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Viral Vaccine
3.2.1. Vaccine Components
3.2.2. Historical Evolution
3.2.3. Viral Vaccine Development
3.3. Type of Viral Vaccine
3.3.1. Whole Virus
3.3.2. Protein Subunit
3.3.3. Nucleic Acid
3.3.4 Viral Vector
3.4. Type of Cell Culture
3.5. Type of Cell Culture Media
3.6. Advantages of Cell Culture Media
3.7. Limitations Associated with Cell Culture Media
3.8. Conclusion

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Viral Vaccine Cell Culture Media: Overall Market Landscape
4.2.1. Analysis by Type of Vaccine
4.2.2. Analysis by Type of Cell Culture
4.2.3. Analysis by Type of Cell Culture Media
4.2.4. Analysis by Type of Cell Culture and Media
4.2.5. Analysis by Type of Cell Line
4.2.6. Analysis by Type of Cell Culture Media and Type of Cell Line
4.2.7. Analysis by Media Formulation
4.2.8. Analysis by Application Area

4.3. Viral Vaccine Cell Culture Media Developers: Market Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Number of Products

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Players based in North America
5.2.1. Creative Biolabs
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Product Portfolio
5.2.1.4. Future Outlook

5.2.2. Jianshun Biosciences
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Product Portfolio
5.2.2.4. Future Outlook

5.2.3. Thermo Fisher Scientific
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Product Portfolio
5.2.3.4. Future Outlook

5.3. Players based in Europe
5.3.1. Merck
5.3.1.1. Company Overview
5.3.1.2. Financial Information
5.3.1.3. Product Portfolio
5.3.1.4. Future Outlook

5.3.2. Sartorius
5.3.2.1. Company Overview
5.3.2.2. Financial Information
5.3.2.3. Product Portfolio
5.3.2.4. Future Outlook

5.3.3. Xell
5.3.3.1. Company Overview
5.3.3.2. Financial Information
5.3.3.3. Product Portfolio
5.3.3.4. Future Outlook

5.4. Players based in Asia-Pacific
5.4.1. ATZ labs
5.4.1.1. Company Overview
5.4.1.2. Financial Information
5.4.1.3. Product Portfolio
5.4.1.4. Future Outlook

5.4.2. OPM Biosciences
5.4.2.1. Company Overview
5.4.2.2. Financial Information
5.4.2.3. Product Portfolio
5.4.2.4. Future Outlook

6. RECENT DEVELOPMENTS AND INITIATIVES 
6.1. Chapter Overview
6.2. Partnership Models
6.3. Viral Vaccine Cell Culture Media: Recent Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.2.1. Analysis by Year and Type of Partnership
6.3.2.2. Analysis by Type of Partnership and Company Size
6.3.3. Most Active Players: Analysis by Number of Partnerships
6.3.4. Regional Analysis
6.3.4.1. Intercontinental and Intracontinental Agreements

6.3.5. Cumulative Year-wise Trend of Merger / Acquisition
6.3.6. Analysis by Type of Acquisition
6.3.7. Analysis by Key Value Drivers
6.3.8. Analysis by Year of Acquisition and Key Value Drivers

6.4. Viral Vaccine Cell Culture Media: Recent Expansions

7. LIKELY PARTNER ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology

7.3. Potential Strategic Partners for Viral Vaccine Cell Culture Media Developers
7.3.1. Likely Partner Opportunities in Preventive Vaccine Developers
7.3.2. Likely Partner Opportunities in Therapeutic Vaccine Developers
7.3.3. Likely Partner Opportunities in Vaccine Contract Manufacturers

8. PRODUCT COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Assumptions / Key Parameters
8.4. Product Competitiveness: Adherent Cell Culture Media
8.5. Product Competitiveness: Suspension Cell Culture Media

9. BRAND POSITIONING
9.1. Chapter Overview
9.2. Key Parameters and Methodology
9.3. Brand Positioning Matrix: Cytiva
9.4. Brand Positioning Matrix: FUJIFILM Wako Chemicals
9.5. Brand Positioning Matrix: Lonza
9.6. Brand Positioning Matrix: Merck
9.7. Brand Positioning Matrix: Sartorius
9.8. Brand Positioning Matrix: Thermo Fisher Scientific

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology

10.3. Viral Vaccine Cell Culture Media: Patent Analysis
10.3.1. Analysis by Type of Patent
10.3.2. Analysis by Publication Year
10.3.3. Analysis by Granted Patents
10.3.4. Year-wise Trend of Filed Patent Applications
10.3.5. Analysis by Issuing Authority
10.3.6. Analysis by Patent Focus
10.3.7. Analysis by Patent Age
10.3.8. Analysis by CPC Symbols
10.3.9. Analysis by Type of Applicant
10.3.10. Leading Players: Analysis by Number of Patents

10.4. Viral Vaccine Cell Culture Media: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.2. Analysis by Geography

10.5. Viral Vaccine Cell Culture Media: Patent Valuation Analysis

11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology

11.3. Global Demand for Viral Vaccine
11.3.1. Global Demand for Scale of Operation
11.3.1.1. Clinical Demand for Viral Vaccine
11.3.1.2. Commercial Demand for Viral Vaccine

11.4.1. Geographical Analysis of Demand
11.4.1.1. Overall Demand in North America for Viral Vaccine
11.4.1.2. Overall Demand in Europe for Viral Vaccine
11.4.1.3. Overall Demand in Asia-Pacific and Rest of the World for Viral Vaccine

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Viral Vaccine Cell Culture Media Market, 2022-2035

12.4. Viral Vaccine Cell Culture Media Market: Analysis by Type of Cell Culture, 2022-2035
12.4.1. Viral Vaccine Cell Culture Media Market for Adherent Cell Culture, 2022-2035
12.4.2. Viral Vaccine Cell Culture Media Market for Suspension Cell Culture, 2022-2035

12.5. Viral Vaccine Cell Culture Media Market: Analysis by Type of Cell Culture Media, 2022-2035
12.5.1. Viral Vaccine Cell Culture Media Market for Animal Component Free Media, 2022-2035
12.5.2. Viral Vaccine Cell Culture Media Market for Protein Free Media, 2022-2035
12.5.3. Viral Vaccine Cell Culture Media Market for Serum Free Media, 2022-2035

12.6. Viral Vaccine Cell Culture Media Market: Analysis by Scale of Operation, 2022-2035
12.6.1. Viral Vaccine Cell Culture Media Market for Clinical Operations, 2022-2035
12.6.2. Viral Vaccine Cell Culture Media Market for Commercial Operations, 2022-2035

12.7. Viral Vaccine Cell Culture Media Market: Analysis by Type of End-User, 2022-2035
12.7.1. Viral Vaccine Cell Culture Media Market for Industry Players, 2022-2035
12.7.2. Viral Vaccine Cell Culture Media Market for Non-Industry Players, 2022-2035

12.8. Viral Vaccine Cell Culture Media Market: Analysis by Geography, 2022-2035
12.8.1. Viral Vaccine Cell Culture Media Market in North America, 2022-2035
12.8.2. Viral Vaccine Cell Culture Media Market in Europe, 2022-2035
12.8.3. Viral Vaccine Cell Culture Media Market in Asia-Pacific, 2022-2035
12.8.4. Viral Vaccine Cell Culture Media Market in Rest of the World, 2022-2035

13. CONCLUSION
13.1. Chapter Overview

14. INTERVIEW TRANSCRIPT(S)

15. APPENDIX I: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Recent Developments and Initiatives
Figure 2.3 Executive Summary: Patent Analysis
Figure 2.4 Executive Summary: Demand Analysis
Figure 2.5 Executive Summary: Market Forecast
Figure 3.1 Components of Vaccine
Figure 3.2 Stages of Viral Vaccine Development
Figure 3.3 Types of Viral Vaccines
Figure 3.4 Types of Cell Culture Media
Figure 4.1 Viral Vaccine Cell Culture Media: Distribution by Types of Vaccines
Figure 4.2 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture
Figure 4.3 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture Media
Figure 4.4 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture and Media
Figure 4.5 Viral Vaccine Cell Culture Media: Distribution by Type of Cell Line
Figure 4.6 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture Media and Type of Cell Line
Figure 4.7 Viral Vaccine Cell Culture Media: Distribution by Application Area
Figure 4.8 Viral Vaccine Cell Culture Media Developers: Distribution by Year of Establishment
Figure 4.9 Viral Vaccine Cell Culture Media Developers: Distribution by Company Size
Figure 4.10 Viral Vaccine Cell Culture Media Developers: Distribution by Location of Headquarters
Figure 4.11 Most Active Players: Distribution by Number of Products
Figure 5.1 Thermo Fisher Scientific: Annual Revenues, 2016 – 9M 2021 (USD Billion)
Figure 5.2 Merck: Annual Revenues, 2016 – 9M 2021 (EUR Billion)
Figure 5.3 Sartorius: Annual Revenues, 2016 – 9M 2021 (EUR Million)
Figure 6.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 6.2 Partnerships and Collaborations: Distribution by Types of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Year and Types of Partnership
Figure 6.4 Partnerships and Collaborations: Distribution by Types of Partnership and Company Size
Figure 6.5 Most Active Players: Distribution by Number of Partnerships
Figure 6.6 Partnerships and Collaborations: Regional Distribution
Figure 6.7 Partnerships and Collaborations: Country-wise Distribution
Figure 6.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Brand Positioning Analysis: Competitive Advantage of Key Industrial Players
Figure 9.2 Brand Positioning Analysis: Reasons to Believe
Figure 9.3 Brand Positioning Matrix: Cytiva
Figure 9.4 Brand Positioning Matrix: FUJIFILM Wako Chemicals
Figure 9.5 Brand Positioning Matrix: Lonza
Figure 9.6 Brand Positioning Matrix: Merck
Figure 9.7 Brand Positioning Matrix: Sartorius
Figure 9.8 Brand Positioning Matrix: Thermo Fisher Scientific
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Distribution by Publication Year, 2015-2021
Figure 10.3 Patent Analysis: Distribution of Granted Patents by Publication Year, 2015-2021
Figure 10.4 Patent Analysis: Distribution of Filed Patents by Publication Year, 2015-2021
Figure 10.5 Patent Analysis: Distribution by Issuing Authority
Figure 10.6 Patent Analysis: Distribution by Patent Focus
Figure 10.7 Patent Analysis: Distribution by Patent Age
Figure 10.8 Patent Analysis: Distribution by CPC Symbols
Figure 10.9 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant (2015 - 2021)
Figure 10.10 Leading Players Assignees: Distribution by Number of Patents
Figure 10.11 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
Figure 10.12 Patent Analysis: Benchmarking by International Patents
Figure 10.13 Patent Valuation Analysis
Figure 11.1 Clinical Demand for Viral Vaccine, 2022-2035 (Million Liters)
Figure 11.2 Commercial Demand for Viral Vaccine, 2022-2035 (Million Liters)
Figure 11.3 Global Demand for Viral Vaccine in North America, 2022-2035 (Million Liters)
Figure 11.4 Global Demand for Viral Vaccine in Europe, 2022-2035 (Million Liters)
Figure 11.5 Global Demand for Viral Vaccine in Asia-Pacific and Rest of the World, 2022-2035 (Million Liters)
Figure 12.1 Global Viral Vaccine Cell Culture Media Market, 2022-2035 (USD Billion)
Figure 12.2 Viral Vaccine Cell Culture Media Market: Distribution by Types of Cell Culture, 2022 and 2032
Figure 12.3 Viral Vaccine Cell Culture Media Market for Adherent Cell Culture, 2022-2035 (USD Million)
Figure 12.4 Viral Vaccine Cell Culture Media Market for Suspension Cell Culture, 2022-2035 (USD Million)
Figure 12.5 Viral Vaccine Cell Culture Media Market: Distribution by Types of Cell Culture Media, 2022 and 2032
Figure 12.6 Viral Vaccine Cell Culture Media Market for Animal Component Free Media, 2022-2035 (USD Million)
Figure 12.7 Viral Vaccine Cell Culture Media Market for Protein Free Media, 2022-2035 (USD Million)
Figure 12.8 Viral Vaccine Cell Culture Media Market for Serum Free Media, 2022-2035 (USD Million)
Figure 12.9 Viral Vaccine Cell Culture Media Market: Distribution by Scale of Operation, 2022 and 2032
Figure 12.10 Viral Vaccine Cell Culture Media Market for Clinical Operations, 2022-2035 (USD Million)
Figure 12.11 Viral Vaccine Cell Culture Media Market for Commercial Operations, 2022-2035 (USD Million)
Figure 12.12 Viral Vaccine Cell Culture Media Market: Distribution by Types of End-User, 2022 and 2032
Figure 12.13 Viral Vaccine Cell Culture Media Market for Industry Players, 2022-2035 (USD Million)
Figure 12.14 Viral Vaccine Cell Culture Media Market for Non-Industry Players, 2022-2035 (USD Million)
Figure 12.15 Viral Vaccine Cell Culture Media Market: Distribution by Geography, 2022 and 2032
Figure 12.16 Viral Vaccine Cell Culture Media Market in North America, 2022-2035 (USD Million)
Figure 12.17 Viral Vaccine Cell Culture Media Market in Europe, 2022-2035 (USD Million)
Figure 12.18 Viral Vaccine Cell Culture Media Market in Asia-Pacific, 2022-2035 (USD Million)
Figure 12.19 Viral Vaccine Cell Culture Media Market in Rest of the World, 2022-2035 (USD Million)
Figure 13.1 Concluding Remarks: Current Market Landscape
Figure 13.2 Concluding Remarks: Recent Developments and Initiatives
Figure 13.3 Concluding Remarks: Patent Analysis
Figure 13.4 Concluding Remarks: Demand Analysis
Figure 13.5 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Comparison between Adherent and Suspension Cell Culture
Table 4.1 Viral Vaccine Cell Culture Media: Information on Developer, Types of Vaccine, and Virus Cultured
Table 4.2 Viral Vaccine Cell Culture Media: Information on Types of Cell Culture and Types of Cell Culture Media
Table 4.3 Viral Vaccine Cell Culture Media: Information on Type of Cell Line
Table 4.4 Viral Vaccine Cell Culture Media: Information on Media Formulation, Available Package Volume and Price
Table 4.5 Viral Vaccine Cell Culture Media: Information on Application Area, Accreditations Received, Types of End-User and Scale of Operation
Table 4.6 Viral Vaccine Cell Culture Media Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 5.1 Creative Biolabs: Company Snapshot
Table 5.2 Creative Biolabs: Product Portfolio
Table 5.3 Jianshun Biosciences: Company Snapshot
Table 5.4 Jianshun Biosciences: Product Portfolio
Table 5.5 Thermo Fisher Scientific: Company Snapshot
Table 5.6 Thermo Fisher Scientific: Product Portfolio
Table 5.7 Merck: Company Snapshot
Table 5.8 Merck: Product Portfolio
Table 5.9 Merck: Recent Developments and Future Outlook
Table 5.10 Sartorius: Company Snapshot
Table 5.11 Sartorius: Product Portfolio
Table 5.12 Sartorius: Recent Developments and Future Outlook
Table 5.13 Xell: Company Snapshot
Table 5.14 Xell: Product Portfolio
Table 5.15 Xell: Recent Developments and Future Outlook
Table 5.16 ATZ labs: Company Snapshot
Table 5.17 ATZ labs: Product Portfolio
Table 5.18 OPM Biosciences: Company Snapshot
Table 5.19 OPM Biosciences: Product Portfolio
Table 6.1 Partnerships and Collaborations: List of Partnership, 2015-2021
Table 6.2 Viral Vaccine Cell Culture Media: List of Recent Expansions, 2015-2021
Table 7.1 Likely Partners for Preventive Vaccine Developers
Table 7.2 Likely Partners for Therapeutic Vaccine Developers
Table 7.3 Likely Partners for Vaccine Contract Manufacturers
Table 8.1 Product Competitiveness Analysis: Adherent Cell Culture Media
Table 8.2 Product Competitiveness Analysis: Suspension Cell Culture Media
Table 10.1 Patent Analysis: Distribution by CPC Symbols
Table 10.2 Patent Analysis: Most Popular CPC Symbols
Table 10.3 Patent Analysis: List of Top CPC Symbols
Table 10.4 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 10.5 Leading Patents: Distribution by Number of Citations
Table 13.1 Conclusion: Overall Market Landscape
Table 13.2 Conclusion: Recent Developments and Initiatives
Table 13.3 Conclusion: Patent Analysis
Table 13.4 Conclusion: Demand Analysis
Table 13.5 Conclusion: Market Forecast
Table 15.1 Viral Vaccine Cell Culture Media: Distribution by Types of Vaccines
Table 15.2 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture
Table 15.3 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture Media
Table 15.4 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture and Media
Table 15.5 Viral Vaccine Cell Culture Media: Distribution by Type of Cell Line
Table 15.6 Viral Vaccine Cell Culture Media: Distribution by Types of Cell Culture Media and Type of Cell Line
Table 15.7 Viral Vaccine Cell Culture Media: Distribution by Media Formulation
Table 15.8 Viral Vaccine Cell Culture Media: Distribution by Application Area
Table 15.9 Viral Vaccine Cell Culture Media Developers: Distribution by Year of Establishment
Table 15.10 Viral Vaccine Cell Culture Media Developers: Distribution by Company Size
Table 15.11 Viral Vaccine Cell Culture Media Developers: Distribution by Location of Headquarters
Table 15.12 Most Active Players: Distribution by Number of Products
Table 15.13 Thermo Fisher Scientific: Annual Revenues, 2016 –9M 2021 (USD Billion)
Table 15.14 Merck: Annual Revenues, 2016 –9M 2021 (EUR Billion)
Table 15.15 Sartorius: Annual Revenues, 2016 – 9M 2021 (EUR Million)
Table 15.16 Partnerships and Collaborations: Distribution by Year of Partnership
Table 15.17 Partnerships and Collaborations: Distribution by Types of Partnership
Table 15.18 Partnerships and Collaborations: Distribution by Year and Types of Partnership
Table 15.19 Partnerships and Collaborations: Distribution by Types of Partnership and Company Size
Table 15.20 Most Active Players: Distribution by Number of Partnerships
Table 15.21 Partnerships and Collaborations: Regional Distribution
Table 15.22 Partnerships and Collaborations: Country-wise Distribution
Table 15.23 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 15.24 Patent Analysis: Distribution by Type of Patent
Table 15.25 Patent Analysis: Cumulative Distribution by Publication Year, 2015 – 2021
Table 15.26 Patent Analysis: Distribution of Granted Patents by Publication Year, 2015-2021
Table 15.27 Patent Analysis: Distribution of Filed Patents by Publication Year, 2015 - 2021
Table 15.28 Patent Analysis: Distribution by Issuing Authority
Table 15.29 Patent Analysis: Distribution by Patent Age
Table 15.30 Patent Analysis: Distribution by CPC Symbols
Table 15.31 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant (2015 - 2021)
Table 15.32 Leading Players Assignees: Distribution by Number of Patents
Table 15.33 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
Table 15.34 Patent Analysis: Benchmarking by International Patents
Table 15.35 Patent Valuation Analysis
Table 15.36 Clinical Demand for Viral Vaccine, 2022-2035 (Million Liters)
Table 15.37 Commercial Demand for Viral Vaccine, 2022-2035 (Million Liters)
Table 15.38 Global Demand for Viral Vaccine in North America, 2022-2035 (Million Liters)
Table 15.39 Global Demand for Viral Vaccine in Europe, 2022-2035 (Million Liters)
Table 15.40 Global Demand for Viral Vaccine in Asia-Pacific and Rest of the World, 2022-2035 (Million Liters)
Table 15.41 Global Viral Vaccine Cell Culture Media Market, 2022-2035 (USD Billion)
Table 15.42 Viral Vaccine Cell Culture Media Market: Distribution by Types of Cell Culture, 2022 and 2032
Table 15.43 Viral Vaccine Cell Culture Media Market for Adherent Cell Culture, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 15.44 Viral Vaccine Cell Culture Media Market for Suspension Cell Culture, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 15.45 Viral Vaccine Cell Culture Media Market: Distribution by Types of Cell Culture Media, 2022 and 2032
Table 15.46 Viral Vaccine Cell Culture Media Market for Animal Component Free Media, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 15.47 Viral Vaccine Cell Culture Media Market for Protein Free Media, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 15.48 Viral Vaccine Cell Culture Media Market for Serum Free Media, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 15.49 Viral Vaccine Cell Culture Media Market: Distribution by Scale of Operation, 2022 and 2032
Table 15.50 Viral Vaccine Cell Culture Media Market for Clinical Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 15.51 Viral Vaccine Cell Culture Media Market for Commercial Operations, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 15.52 Viral Vaccine Cell Culture Media Market: Distribution by Types of End-User, 2022 and 2032
Table 15.53 Viral Vaccine Cell Culture Media Market for Industry Players, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 15.54 Viral Vaccine Cell Culture Media Market for Non-Industry Players, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 15.55 Viral Vaccine Cell Culture Media Market: Distribution by Geography, 2022 and 2032
Table 15.56 Viral Vaccine Cell Culture Media Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 15.57 Viral Vaccine Cell Culture Media Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 15.58 Viral Vaccine Cell Culture Media Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 15.59 Viral Vaccine Cell Culture Media Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 2BScientific
  2. Adimmune
  3. Aduro Biotech
  4. Advagene Biopharma
  5. Advanced Bioprocessing Business (A subsidiary of Thermo Fisher Scientific)
  6. Advanced BioScience Laboratories
  7. Advent
  8. AJ Biologics
  9. Albany Molecular Research
  10. Alopexx Vaccine
  11. Altimmune
  12. Amphera
  13. Anhui Zhifei Longcom Biologic Pharmacy
  14. Applied Biosystems
  15. Argos Therapeutics
  16. Astellas Pharma
  17. Asterias Biotherapeutics
  18. ATZ labs
  19. Auro Vaccines
  20. Aurora Biopharma
  21. AVAX Technologies
  22. Avid Bioservices
  23. AVIR Green Hills Biotechnology
  24. Batavia Biosciences
  25. Bavarian Nordic
  26. BD Biosciences
  27. Beijing Minhai Biotechnology
  28. Beijing Zhifei Lvzhu Biopharmaceutical
  29. Bharat Biotech
  30. Bielefeld University
  31. Bio Farma
  32. BioCell
  33. BioConnection
  34. Biofabri
  35. Biological E
  36. Biological Industries
  37. BioMARC
  38. BioReliance
  39. BlueWillow Biologics
  40. Boehringer Ingelheim
  41. Boryung Pharmaceutical
  42. BravoVax
  43. Bryllan
  44. CanSino Biologics
  45. Capricorn Scientific
  46. Catalent Biologics
  47. Cellca (Acquired by Sartorius)
  48. CellGenix
  49. CEVEC Pharmaceuticals
  50. Charles River Laboratories
  51. Chengdu Zenmindes Biotechnology
  52. CiMaas
  53. CJ HealthCare
  54. Cobra Biologics
  55. Codagenix
  56. Commonwealth Serum Laboratories (CSL)
  57. Creative Biolabs
  58. Curevo Vaccine
  59. Cytiva
  60. CyTuVax
  61. Daiichi Sankyo
  62. DanDrit Biotech
  63. DCPrime
  64. Dendreon
  65. Elios Therapeutics
  66. Emergent BioSolutions
  67. Fisher Scientific (Acquired by Thermo Fisher Scientific)
  68. FluGen
  69. FUJIFILM Wako Pure Chemicals
  70. GC Pharma
  71. GeneOne Life Science
  72. GlaxoSmithKline
  73. Gradalis
  74. HALIX
  75. Heat Biologics
  76. Hilleman Laboratories
  77. Hookipa Biotech
  78. Icahn School of Medicine at Mount Sinai
  79. IDT Biologika
  80. ILiAD Biotechnologies
  81. Immunicum
  82. ImmunoCellular Therapeutics
  83. Immutep
  84. Indian Immunologicals
  85. Inovio Pharmaceuticals
  86. Institut National de la Santé et de la Recherche Médicale (INSERM)
  87. Insud Pharma
  88. Intermountain Life Sciences
  89. Intervet
  90. InVitria
  91. Invitrogen
  92. Irvine Scientific Sales (Acquired by FUJIFILM)
  93. IS JAPAN (Acquired by FUJIFILM)
  94. Janssen Pharmaceuticals
  95. Jianshun Biosciences
  96. JN International Medical
  97. JW CreaGene
  98. Kansas State University
  99. KBI Biopharma
  100. Kiromic
  101. Leland Stanford Junior University
  102. LG Chem
  103. LimmaTech Biologics
  104. Lonza
  105. Luina Bio
  106. Massachusetts Institute of Technology
  107. MassBiologics
  108. Medicago
  109. Medigen Vaccine Biologics
  110. Medigene
  111. Meissa Vaccines
  112. Merck
  113. Meridian Life Science
  114. MilliporeSigma
  115. MinervaX
  116. Moderna
  117. MolecuVax
  118. Northwest Biotherapeutics
  119. Nova Immunotherapeutics
  120. Novartis
  121. Novasep
  122. Novavax
  123. NPO Petrovax Pharm
  124. Ology Bioservices
  125. Oncobiomed
  126. OPM Biosciences
  127. Osivax
  128. Oxford Biomedica
  129. Pall Corporation
  130. Panacea Biotec
  131. Patheon Viral Vector Services
  132. PDC*line Pharma
  133. Pfizer
  134. Premas Biotech
  135. Prestige BioPharma
  136. ProBioGen
  137. Regeneus
  138. Research Institute at Nationwide Children's Hospital
  139. Sanaria
  140. Sanofi Pasteur
  141. Saronic Biotechnology
  142. Sartorius
  143. Scandinavian Biopharma
  144. Seqirus 
  145. Serum Institute of India
  146. Shanghai Bovax Biotechnology
  147. Shenzhen Hornetcorn Biotechnology
  148. Shenzhen Kangtai Biological Products
  149. Sigma-Aldrich
  150. SK Bioscience
  151. SOTIO
  152. Symbiosis Pharmaceutical Services
  153. Takeda
  154. TapImmune
  155. Tella
  156. Tessa Therapeutics
  157. TeutoCell
  158. Themis Bioscience
  159. Thermo Electron
  160. Thermo Fisher Scientific
  161. Thousand Oaks Biopharmaceuticals
  162. TNCbio
  163. Unity Lab Services
  164. University of California
  165. University of Pennsylvania
  166. University of Texas
  167. USHEALTH
  168. Vaccinogen
  169. Vaccitech
  170. Valneva
  171. Vaxart
  172. Vaxine
  173. Vibalogics
  174. Waisman Biomanufacturing
  175. WuXi Biologics
  176. Xell
  177. XEME Biopharma

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com